MAPK3 and Miyoshi myopathy: The clinical potential of Erk1/2i + CDK4/6i was further supported by in vivo study demonstrating a significant (P = 0.0004) decrease of the MM burden in Erk1/2i + CDK4/6i-treated mice compared to the vehicle-treated control, without adverse effects.